Division of Genetics and Development, Toronto Western Research Institute, Toronto, Ontario M5T 2S8, Canada.
J Cell Physiol. 2010 Mar;222(3):515-21. doi: 10.1002/jcp.21995.
Despite advances in medical and surgical care, current clinical therapies for spinal cord injury (SCI) are limited. During the last two decades, the search for new therapies has been revolutionized by the discovery of stem cells, inspiring scientists and clinicians to search for stem cell-based reparative approaches for many disorders, including neurotrauma. Cell-based therapies using embryonic and adult stem cells in animal models of these disorders have provided positive outcome results. However, the availability of clinically suitable cell sources for human application has been hindered by both technical and ethical issues. The recent discovery of induced pluripotent stem (iPS) cells holds the potential to revolutionize the field of regenerative medicine by offering the option of autologous transplantation, thus eliminating the issue of host rejection. Herein, we will provide the rationale for the use of iPS cells in SCI therapies. In this review, we will evaluate the recent advancements in the field of iPS cells including their capacity for differentiation toward neural lineages that may allow iPS cells transplantation in cell-based therapy for spinal cord repair.
尽管在医学和外科治疗方面取得了进展，但目前治疗脊髓损伤 (SCI) 的临床疗法仍然有限。在过去的二十年中，干细胞的发现彻底改变了新疗法的探索，激发了科学家和临床医生寻找基于干细胞的修复方法来治疗许多疾病，包括神经创伤。在这些疾病的动物模型中使用胚胎和成体干细胞的细胞疗法已经提供了积极的结果。然而，由于技术和伦理问题，临床适用的人类细胞来源的可用性受到了阻碍。最近诱导多能干细胞 (iPS) 的发现有可能通过提供自体移植的选择来彻底改变再生医学领域，从而消除宿主排斥的问题。在此，我们将提供使用 iPS 细胞治疗 SCI 的基本原理。在这篇综述中，我们将评估 iPS 细胞领域的最新进展，包括其向神经谱系分化的能力，这可能允许 iPS 细胞移植用于基于细胞的脊髓修复治疗。
